Robert A. Drakas

ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California.

Azkarra Therapeutics, Inc. is a medical research and development company that specializes in providing oncology therapies based on DNA damage response. The company is based in South San Francisco, CA. Mohamad Tabrizi has been the CEO of the company since 2019.

Blue Oak Pharmaceuticals, Inc. is a therapeutics developer for brain disorders. Its research is in finding the next generation of drugs for the brain disorders to help patients by creating new medicines, transform the CNS drug discovery paradigm, and achieve rapid clinical neurobiology measures and translational biomarkers. The company was founded by Thomas H. Large and Kerry L. Spear in 2016 and is headquartered in Concord, MA.

Shangpharma Corp. provides pharmaceutical and biotechnology research outsourcing services. It offers various integrated services across the drug discovery and development process to international and chinese pharmaceutical and biotechnology companies, and academic and research institutions. The company was founded by Michael Xin Hui and Wenjuan Xiao in 2002 and is headquartered in Shanghai, China.

Shanghai ChemPartner Co., Ltd. operates as a contract research organization. It provides chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, and analytical development services to global pharmaceutical and biotech companies. The company was founded in 2003 and is headquartered in Shanghai, China.